Paeoniflorin
| Code | Size | Price |
|---|
| CDX-P0260-M025 | 25 mg | £48.00 |
Quantity:
| CDX-P0260-M100 | 100 mg | £108.00 |
Quantity:
| CDX-P0260-M250 | 250 mg | £242.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+20°C
Documents
Further Information
Alternate Names/Synonyms:
NSC 178886
Appearance:
White to off-white powder.
CAS:
23180-57-6
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1
InChiKey:
YKRGDOXKVOZESV-WRJNSLSBSA-N
Long Description:
Chemical. CAS: 23180-57-6. Formula: C23H28O11. MW: 480.46. Paeoniflorin has diverse cellular actions, including modulating NMDA and TRPV1 receptors. It is reported to inhibit testosterone synthesis and stimulate aromatase activity. It also reduces inflammatory signaling by inhibiting p38 MAP kinase and blocks pancreatic cancer cell apoptosis by suppressing MMP-2/9 and ERK signaling. It has been described as an adenosine A1 receptor activator with neuroprotective and antidepressant effects, as well as hypoglycemic activity. It can activate adenosine A-1 receptors to increase the translocations of PKC and GLUT4, two major signals for glucose uptake, from cytosol to membrane of the white adipocytes in rats. Recently it also was described as a liver X receptor (LXR) agonist, that can act as a ligand-activated transcription factor to exhibit antihyperlipidemic and neuroprotective effects. In addition, this potential anticancer agent, has ben described as a EP2 receptor agonists, a heat-shock protein (HSP)-inducing compound, by activation of HSF1, or by interacting with NOTCH1 or mTOR/HIF-1 signaling pathways.
MDL:
MFCD00869331
Molecular Formula:
C23H28O11
Molecular Weight:
480.46
Package Type:
Vial
Product Description:
Paeoniflorin has diverse cellular actions, including modulating NMDA and TRPV1 receptors. It is reported to inhibit testosterone synthesis and stimulate aromatase activity. It also reduces inflammatory signaling by inhibiting p38 MAP kinase and blocks pancreatic cancer cell apoptosis by suppressing MMP-2/9 and ERK signaling. It has been described as an adenosine A1 receptor activator with neuroprotective and antidepressant effects, as well as hypoglycemic activity. It can activate adenosine A-1 receptors to increase the translocations of PKC and GLUT4, two major signals for glucose uptake, from cytosol to membrane of the white adipocytes in rats. Recently it also was described as a liver X receptor (LXR) agonist, that can act as a ligand-activated transcription factor to exhibit antihyperlipidemic and neuroprotective effects. In addition, this potential anticancer agent, has ben described as a EP2 receptor agonists, a heat-shock protein (HSP)-inducing compound, by activation of HSF1, or by interacting with NOTCH1 or mTOR/HIF-1 signaling pathways.
Purity:
>98% (HPLC)
SMILES:
O[C@]12O[C@@]3([H])O[C@](C2)(C)[C@@]4([C@@]3(COC(C5=CC=CC=C5)=O)[C@@]1([H])C4)O[C@@H]([C@@H]([C@H]6O)O)O[C@H](CO)[C@H]6O
Solubility Chemicals:
Soluble in DMSO, DMF, ethanol (all 20mg/ml) or water (10mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at RT.
References
(1) J. Yamahara, et al.; J. Pharmacobiodyn. 5, 921 (1982) | (2) T. Takeuchi, et al.; Amer. J. Chin. Med. 19, 73 (1991) | (3) F.L. Hsu, et al.; Planta Med. 63, 323 (1997) | (4) C.W. Lai, et al.; Life Sci. 62, 1591 (1998) | (5) H.O. Yang, et al.; Fitoterapia 75, 45 (2004) | (6) D. Yan, et al.; Cell Stress Chaperones 9, 378 (2004) | (7) D.Z. Liu, et al.; Br. J. Pharmacol. 146, 604 (2005) | (8) H.Q. Liu, et al.; Br. J. Pharmacol. 148, 314 (2006) | (9) J.Y. Hung, et al.; Clin. Exp. Pharmacol. Physiol. 35, 141 (2008) | (10) H. Wu, et al.; Biomed. Pharmacother. 62, 659 (2008) | (11) J. Fu, et al.; Comp. Med. 59, 557 (2009) | (12) J. Huang, et al.; Int. Immunopharmacol. 10, 1279 (2010) | (13) Q.Q. Mao, et al.; Phytother. Res. 25, 681 (2011) | (14) S. Hu, et al.; Anticancer Drugs 24, 140 (2013) | (15) R.B. Guo, et al.; PLoS One 7, e49701 (2012) | (16) H.R. Lin; J. Asian Nat. Prod. Res. 15, 35 (2013) | (17) F.M. Qiu, et al.; Neurosci. Lett. 541, 209 (2013) | (18) W. Li, et al.; Mol. Med. Rep. 12, 2735 (2015) | (19) F. Han, et al.; Cell Biosci. 6, 37 (2016) | (20) S. Wang & W. Liu; Mol. Med. Rep. 14, 2143 (2016) | (21) R. Lu, et al.; Biomed. Pharmacother. 96, 137 (2017) | (22) J. Zhang, et al.; Mol. Med. Rep. 17, 1321 (2018) | (23) H. Wang, et al.; J. Cell Physiol. (Epub ahead of print) (2018) | (24) L.B. Jin, et al.; Mol. Med. Rep. 17, 5095 (2018)